Page last updated: 2024-11-13

srt1720

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID24180125
CHEMBL ID257991
SCHEMBL ID963877
MeSH IDM0517100

Synonyms (44)

Synonym
HY-10532
n-(2-(3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide
bdbm50228363
srt-1720
CHEMBL257991 ,
NCGC00182052-02
NCGC00182052-01
NCGC00182052-03
srt1720 ,
srt 1720
925434-55-5
AKOS016001425
n-{2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl}quinoxaline-2-carboxamide
CS-0437
gtpl7703
n-[2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide
dx3fhy76fz ,
unii-dx3fhy76fz
SCHEMBL963877
n-[2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide
tafluprost enone
J-690391
n-[2-[3-(1-piperazinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]-2-quinoxalinecarboxamide
DTXSID00636045
EX-A033
IASPBORHOMBZMY-UHFFFAOYSA-N ,
NCGC00182052-06
FT-0753807
srt1720 - cas 925434-55-5
srt-1720 free base
925434-55-5 (free base)
EX-A7228
AS-17063
n-(2-{3-[(piperazin-1-yl)methyl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl)quinoxaline-2-carboxamide
Q7392863
n-(2-(3-(1-piperazinylmethyl)imidazo(2,1-b)thiazol-6-yl)phenyl)-2-quinoxalinecarboxamide
2-quinoxalinecarboxamide, n-(2-(3-(1-piperazinylmethyl)imidazo(2,1-b)thiazol-6-yl)phenyl)-
925435-64-9
SB19332
AMY36693
BCP13176
F3390-0301
NCGC00182052-12
AC-35736

Research Excerpts

Overview

SRT1720 is an activator of SIRT1, a NAD(+)-dependent protein and histone deacetylase. It has health and lifespan benefits in adult mice fed a high-fat diet.

ExcerptReferenceRelevance
"SRT1720 is a specific sirtuin-1 activator."( The investigation of the role of sirtuin-1 on embryo implantation in oxidative stress-induced mice.
Acar, N; Aksu, K; Aslan, MA; Golal, E; Ustunel, I, 2021
)
1.34
"SRT1720 is a newly formulatedSIRT1 activator that exerts multiple pharmacological activities with beneficial health effects."( SRT1720 ameliorates sodium taurocholate-induced severe acute pancreatitis in rats by suppressing NF-κB signalling.
Hou, C; Huang, D; Li, Q; Miao, Y; Peng, Y; Shi, C; Tu, M; Zhu, X, 2018
)
2.64
"SRT1720 is a specific SIRT1 activator that has health and lifespan benefits in adult mice fed a high-fat diet."( The SIRT1 activator SRT1720 extends lifespan and improves health of mice fed a standard diet.
Abulwerdi, G; Allison, DB; Becker, KG; Bernier, M; Dawson, J; de Cabo, R; Ellis, JL; Martin-Montalvo, A; Mercken, EM; Minor, RK; Mitchell, SJ; Palacios, HH; Sinclair, DA; Vlasuk, GP; Ward, TM; Zhang, Y, 2014
)
1.45
"SRT1720 is an activator of SIRT1, a NAD(+)-dependent protein and histone deacetylase that plays an important role in numerous biologic processes. "( SRT1720 induces lysosomal-dependent cell death of breast cancer cells.
Deng, CX; Lahusen, TJ, 2015
)
3.3

Treatment

SRT1720 treatment increased the protein levels of occludin and ZO-1 and inhibited Caco-2 apoptosis. NAM administration caused the opposite effects. SRT1720 upregulated metabolically favorable genes and reduced inflammatory gene expressions in septic mice.

ExcerptReferenceRelevance
"SRT1720 treatment increased the protein levels of occludin and ZO-1 and inhibited Caco-2 apoptosis, whereas NAM administration caused the opposite effects. "( Sirtuin 1 alleviates endoplasmic reticulum stress-mediated apoptosis of intestinal epithelial cells in ulcerative colitis.
Ding, CY; Gu, ML; Ji, F; Pan, HH; Ren, MT; Yu, MS; Zhou, XX, 2019
)
1.96
"SRT1720 treatment (4 μM) significantly reversed these effects in hyperglycemia insulted PC12 cells but silencing the expression of LONP1 impeded this effect of SRT1720 on mitochondrial complex activities, OCR and mitochondrial membrane potential."( LONP1 induction by SRT1720 attenuates mitochondrial dysfunction against high glucose induced neurotoxicity in PC12 cells.
Kalvala, AK; Kumar, A; Yerra, VG, 2020
)
1.61
"SRT1720 treatment produced a dose-dependent analgesic effect on the BCP mice and downregulated the expression of p-CREB and CRTC1."( Intrathecal administration of SRT1720 relieves bone cancer pain by inhibiting the CREB/CRTC1 signalling pathway.
Han, M; Huang, X; Kang, F; Li, J; Wang, S; Yang, C; Zhang, Z, 2020
)
1.57
"SRT1720 treatment resulted in a significantly decreased mRNA expression of inflammasome components (nucleotide oligomerization domain-like receptor protein 3, adapter apoptosis-associated speck-like protein containing caspase-recruitment domain, IL-1β, and IL-18) in the liver, compared with the vehicle group."( SRT1720, a sirtuin 1 activator, attenuates organ injury and inflammation in sepsis.
Coppa, GF; Hansen, LW; Khader, A; Nicastro, JM; Prince, JM; Rajayer, SR; Wang, P; Yang, WL, 2017
)
2.62
"SRT1720 treatment attenuates multiorgan injury in septic mice. "( SRT1720, a sirtuin 1 activator, attenuates organ injury and inflammation in sepsis.
Coppa, GF; Hansen, LW; Khader, A; Nicastro, JM; Prince, JM; Rajayer, SR; Wang, P; Yang, WL, 2017
)
3.34
"SRT1720 treatment upregulated metabolically favorable genes and reduced inflammatory gene expressions in the adipose tissue of diet-induced obese (DIO) mice."( Sirt1 activator induces proangiogenic genes in preadipocytes to rescue insulin resistance in diet-induced obese mice.
Fujisaka, S; Igarashi, Y; Kado, T; Kanatani, Y; Mehmood, A; Nakagawa, T; Nawaz, A; Okabe, K; Takikawa, A; Tobe, K; Yagi, K; Yamamoto, S, 2018
)
1.2
"The SRT1720 treatment produced an analgesic effect on tumor-bearing mice and decreased the spinal levels of the mGluR1/5 protein and mRNA."( SIRT1 Activation Attenuates Bone Cancer Pain by Inhibiting mGluR1/5.
Han, M; Kang, F; Li, J; Wang, S; Yang, C; Zhang, Z, 2019
)
0.99
"SRT1720 treatment enhanced energy metabolism by stimulating mitochondrial biogenesis as well as decreasing nitrosative stress and inflammation, thereby attenuating I/R-induced renal injury."( Sirtuin 1 activation stimulates mitochondrial biogenesis and attenuates renal injury after ischemia-reperfusion.
Asirvatham, JR; Coppa, GF; Jacob, A; Khader, A; Kuncewitch, M; Nicastro, J; Prince, JM; Wang, P; Yang, WL, 2014
)
1.85
"SRT1720 treatment up-regulated the levels of surfactant protein (SP)A, SPC, SIRT1 and forkhead box O 3, increased SIRT1 activity, down-regulated the level of p53 and inhibited AECII apoptosis."( Sirtuin 1 Activator SRT1720 Protects Against Lung Injury via Reduction of Type II Alveolar Epithelial Cells Apoptosis in Emphysema.
Chen, C; Gu, C; Li, Y; Ma, YY; Tao, HQ; Wang, HJ; Xia, YJ; Xu, WL; Yan, JP, 2015
)
1.46
"The SRT1720 treatment of I/R mice resulted in a 57% increase in protein levels of succinate dehydrogenase, an index of mitochondrial mass, and a 120% increase in messenger RNA levels of mitochondrial transcription factor A, a marker for mitochondrial biogenesis."( SIRTUIN 1 ACTIVATOR SRT1720 PROTECTS AGAINST ORGAN INJURY INDUCED BY INTESTINAL ISCHEMIA-REPERFUSION.
Coppa, GF; Hansen, LW; Khader, A; Nicastro, JM; Prince, JM; Wang, P; Yang, WL, 2016
)
1.24
"SRT1720 treatment increased adenosine triphosphate levels and survival of cultured hepatocytes after hypoxia-reoxygenation."( Sirtuin 1 Stimulation Attenuates Ischemic Liver Injury and Enhances Mitochondrial Recovery and Autophagy.
Coppa, GF; Godwin, A; Khader, A; Nicastro, JM; Prince, JM; Wang, P; Yang, WL, 2016
)
1.16
"SRT1720 treatment preserved the myocardial SIRT1 activity and PGC1α deacetylation (active-form) that were decreased by 53% and 9-fold respectively, in chagasic mice."( SIRT1-PGC1α-NFκB Pathway of Oxidative and Inflammatory Stress during Trypanosoma cruzi Infection: Benefits of SIRT1-Targeted Therapy in Improving Heart Function in Chagas Disease.
Garg, NJ; Koo, SJ; Liang, LY; Wan, X; Wen, JJ, 2016
)
1.16
"SRT1720 treatment significantly reduced these levels without affecting body weight or food intake."( Treatment with SRT1720, a SIRT1 activator, ameliorates fatty liver with reduced expression of lipogenic enzymes in MSG mice.
Bukhari, A; Fujisaka, S; Hayashi, R; Hirata, K; Imanishi, S; Ishiki, M; Kanatani, Y; Kobayashi, M; Matsuya, Y; Nemoto, H; Senda, S; Suzuki, H; Tobe, K; Tsuneyama, K; Urakaze, M; Usui, I; Yamazaki, Y, 2009
)
1.43
"Posttreatment with SRT1720 significantly improved renal histologic architecture, decreased apoptosis, and reduced serum aspartate aminotransferase and creatinine levels compared to the vehicle. "( Sirtuin 1 activation stimulates mitochondrial biogenesis and attenuates renal injury after ischemia-reperfusion.
Asirvatham, JR; Coppa, GF; Jacob, A; Khader, A; Kuncewitch, M; Nicastro, J; Prince, JM; Wang, P; Yang, WL, 2014
)
0.73
"Treatment with Srt1720 minimized the trauma-induced decreases in splenocyte proliferation (P < 0.05), whereas treatment with PGC1α siRNA led to diminished bacterial clearance."( Sirtuin 1 Agonist Minimizes Injury and Improves the Immune Response Following Traumatic Shock.
Darwiche, S; Kautza, B; Luciano, JA; Martinez, S; Rosengart, M; Shiva, S; Sperry, J; Stratimirovic, S; Waltz, P; Zuckerbraun, BS, 2015
)
0.76

Bioavailability

ExcerptReferenceRelevance
" The strong effects of resveratrol on the mitochondrial respiratory chain and on glycolysis suggest that caution should be used in attempts to increase bioavailability of this compound in the CNS."( Silent information regulator 1 modulator resveratrol increases brain lactate production and inhibits mitochondrial metabolism, whereas SRT1720 increases oxidative metabolism.
Beart, PM; Klugmann, M; Lau, CL; Rae, CD; Rowlands, BD; Ryall, JG; Thomas, DS, 2015
)
0.62
"Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule."( Highly predictive and interpretable models for PAMPA permeability.
Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017
)
0.46
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Additionally, an ∼85% correlation was obtained between PAMPA pH 5 permeability and in vivo oral bioavailability in mice and rats."( Using in vitro ADME data for lead compound selection: An emphasis on PAMPA pH 5 permeability and oral bioavailability.
Itkin, M; Kabir, M; Mathé, EA; Nguyễn, ÐT; Padilha, EC; Shah, P; Shinn, P; Siramshetty, V; Wang, AQ; Williams, J; Xu, X; Yu, KR; Zhao, T, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (15)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PPM1D proteinHomo sapiens (human)Potency14.74030.00529.466132.9993AID1347411
TDP1 proteinHomo sapiens (human)Potency4.58580.000811.382244.6684AID686978; AID686979
Smad3Homo sapiens (human)Potency35.48130.00527.809829.0929AID588855
EWS/FLI fusion proteinHomo sapiens (human)Potency28.35180.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
67.9K proteinVaccinia virusPotency11.90470.00018.4406100.0000AID720579; AID720580
flap endonuclease 1Homo sapiens (human)Potency26.05890.133725.412989.1251AID588795; AID720498
Interferon betaHomo sapiens (human)Potency14.74030.00339.158239.8107AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Muscarinic acetylcholine receptor M2Homo sapiens (human)IC50 (µMol)6.28000.00001.23267.7930AID347736
Alpha-2A adrenergic receptorHomo sapiens (human)IC50 (µMol)2.83000.00001.44217.3470AID347734
Muscarinic acetylcholine receptor M1Homo sapiens (human)IC50 (µMol)8.02000.00001.403910.0000AID347735
Sodium-dependent noradrenaline transporter Homo sapiens (human)IC50 (µMol)2.47000.00081.541620.0000AID347737
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)10.00000.00091.901410.0000AID347728
NAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)IC50 (µMol)0.85000.85005.430010.0000AID1466439
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
NAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)EC50 (µMol)18.58000.16000.16000.1600AID331041; AID500672
NAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)EC50 (µMol)0.16000.16001.05432.9000AID331040; AID735925
NAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)EC50 (µMol)300.00000.17001.71003.2500AID331042
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
NAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)Activity0.16000.16000.98001.8000AID347335
NAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)EC1.5 (µMol)0.16000.16000.16000.1600AID1896329
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (277)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M2Homo sapiens (human)
regulation of heart contractionMuscarinic acetylcholine receptor M2Homo sapiens (human)
response to virusMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M2Homo sapiens (human)
regulation of smooth muscle contractionMuscarinic acetylcholine receptor M2Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M2Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M2Homo sapiens (human)
positive regulation of cytokine productionAlpha-2A adrenergic receptorHomo sapiens (human)
DNA replicationAlpha-2A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
Ras protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
Rho protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2A adrenergic receptorHomo sapiens (human)
actin cytoskeleton organizationAlpha-2A adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell migrationAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
cellular response to hormone stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2A adrenergic receptorHomo sapiens (human)
vasodilationAlpha-2A adrenergic receptorHomo sapiens (human)
glucose homeostasisAlpha-2A adrenergic receptorHomo sapiens (human)
fear responseAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of potassium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAP kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion-dependent exocytosisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2A adrenergic receptorHomo sapiens (human)
intestinal absorptionAlpha-2A adrenergic receptorHomo sapiens (human)
thermoceptionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of lipid catabolic processAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of membrane protein ectodomain proteolysisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of uterine smooth muscle contractionAlpha-2A adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
phospholipase C-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of wound healingAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transmembrane transporter activityAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of monoatomic ion transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
neuromuscular synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of locomotionMuscarinic acetylcholine receptor M1Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M1Homo sapiens (human)
cognitionMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of postsynaptic membrane potentialMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of glial cell proliferationMuscarinic acetylcholine receptor M1Homo sapiens (human)
positive regulation of intracellular protein transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
monoamine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent noradrenaline transporter Homo sapiens (human)
chemical synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent noradrenaline transporter Homo sapiens (human)
response to painSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent noradrenaline transporter Homo sapiens (human)
neuron cellular homeostasisSodium-dependent noradrenaline transporter Homo sapiens (human)
amino acid transportSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent noradrenaline transporter Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
rDNA heterochromatin formationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
protein deacetylationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
autophagyNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
mitotic nuclear membrane reassemblyNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
regulation of exit from mitosisNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of autophagyNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of peptidyl-threonine phosphorylationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
substantia nigra developmentNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
myelination in peripheral nervous systemNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
heterochromatin formationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
subtelomeric heterochromatin formationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
regulation of myelinationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cellular response to oxidative stressNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
peptidyl-lysine deacetylationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
epigenetic regulation of gene expressionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of protein catabolic processNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
regulation of phosphorylationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of DNA bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
post-translational protein modificationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cellular lipid catabolic processNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NLRP3 inflammasome complex assemblyNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
innate immune responseNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of fat cell differentiationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of fatty acid biosynthetic processNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of meiotic nuclear divisionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of striated muscle tissue developmentNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of DNA-templated transcriptionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cell divisionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
meiotic cell cycleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
regulation of cell cycleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
response to redox stateNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of cell divisionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of attachment of spindle microtubules to kinetochoreNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cellular response to caloric restrictionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of oligodendrocyte progenitor proliferationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cellular response to hypoxiaNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cellular response to epinephrine stimulusNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
tubulin deacetylationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of execution phase of apoptosisNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of oocyte maturationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of NLRP3 inflammasome complex assemblyNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of satellite cell differentiationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
single strand break repairNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
rDNA heterochromatin formationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
pyrimidine dimer repair by nucleotide-excision repairNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
DNA synthesis involved in DNA repairNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
angiogenesisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
ovulation from ovarian follicleNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
intracellular glucose homeostasisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of protein phosphorylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of endothelial cell proliferationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of adaptive immune responseNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
chromatin organizationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
DNA methylation-dependent heterochromatin formationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein deacetylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
triglyceride mobilizationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
DNA damage responseNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
response to oxidative stressNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
spermatogenesisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of mitotic cell cycleNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
muscle organ developmentNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of cell population proliferationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to starvationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of gene expressionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of centrosome duplicationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of triglyceride biosynthetic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of cholesterol effluxNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of lipid storageNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of glucose metabolic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of macroautophagyNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein ubiquitinationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
peptidyl-lysine acetylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
macrophage differentiationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of prostaglandin biosynthetic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
heterochromatin formationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein destabilizationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of TOR signalingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of endodeoxyribonuclease activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
response to insulinNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
circadian regulation of gene expressionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
leptin-mediated signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of smooth muscle cell apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
intracellular triglyceride homeostasisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of peroxisome proliferator activated receptor signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of cell population proliferationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to glucose starvationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of phosphorylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
response to hydrogen peroxideNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
behavioral response to starvationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cholesterol homeostasisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of DNA-binding transcription factor activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediatorNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of neuron apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
response to leptinNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of MHC class II biosynthetic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of fat cell differentiationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of gluconeogenesisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of DNA repairNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of angiogenesisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of cell cycleNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of DNA-templated transcriptionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of transcription by glucoseNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of insulin receptor signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
white fat cell differentiationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of helicase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of smooth muscle cell differentiationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
maintenance of nucleus locationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
fatty acid homeostasisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of androgen receptor signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of macrophage cytokine productionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to hydrogen peroxideNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of bile acid biosynthetic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
UV-damage excision repairNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to tumor necrosis factorNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to hypoxiaNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to ionizing radiationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of protein serine/threonine kinase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of brown fat cell differentiationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
stress-induced premature senescenceNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
energy homeostasisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein depropionylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
DNA repair-dependent chromatin remodelingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of cellular response to heatNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of signal transduction by p53 class mediatorNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of protein acetylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of adipose tissue developmentNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to leukemia inhibitory factorNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of macrophage apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of cAMP-dependent protein kinase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of cAMP-dependent protein kinase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of cellular response to testosterone stimulusNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of peptidyl-lysine acetylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of cellular senescenceNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of cellular senescenceNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of double-strand break repairNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
chromatin remodelingNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
protein deacetylationNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
aerobic respirationNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
positive regulation of insulin secretionNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
peptidyl-lysine deacetylationNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
positive regulation of superoxide dismutase activityNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
positive regulation of catalase activityNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
positive regulation of ceramide biosynthetic processNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
negative regulation of reactive oxygen species metabolic processNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (78)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M2Homo sapiens (human)
arrestin family protein bindingMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M2Homo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein kinase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-1B adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-2C adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
thioesterase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
heterotrimeric G-protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
norepinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2A adrenergic receptorHomo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
actin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
alpha-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
metal ion bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
beta-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
chromatin bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
histone deacetylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
protein bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
zinc ion bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD-dependent histone deacetylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
protein lysine deacetylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD-dependent protein lysine deacetylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
histone acetyltransferase bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
histone deacetylase bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
tubulin deacetylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
ubiquitin bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD-dependent histone H4K16 deacetylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD+ bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
DNA-binding transcription factor bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD-dependent protein demyristoylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD-dependent protein depalmitoylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
transcription factor bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
p53 bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
transcription coactivator activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
transcription corepressor activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
histone deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nuclear receptor bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD-dependent histone deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
enzyme bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD-dependent histone H3K14 deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein lysine deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD-dependent protein lysine deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
histone bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
identical protein bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
HLH domain bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
bHLH transcription factor bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
metal ion bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD-dependent histone H3K9 deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD-dependent histone H4K16 deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
mitogen-activated protein kinase bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
lysine-acetylated histone bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein-propionyllysine depropionylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
DNA-binding transcription factor bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
histone H4K12 deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
histone H3K deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD-dependent histone decrotonylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
keratin filament bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
promoter-specific chromatin bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD+ bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
protein bindingNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
zinc ion bindingNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
enzyme bindingNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
NAD-dependent protein lysine deacetylase activityNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
sequence-specific DNA bindingNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
NAD+ bindingNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
NAD-dependent histone deacetylase activityNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (65)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
clathrin-coated endocytic vesicle membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
asymmetric synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
symmetric synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
neuronal cell bodyMuscarinic acetylcholine receptor M2Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M2Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M2Homo sapiens (human)
cytoplasmAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
basolateral plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
neuronal cell bodyAlpha-2A adrenergic receptorHomo sapiens (human)
axon terminusAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic active zone membraneAlpha-2A adrenergic receptorHomo sapiens (human)
dopaminergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
postsynaptic density membraneAlpha-2A adrenergic receptorHomo sapiens (human)
glutamatergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
GABA-ergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
receptor complexAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M1Homo sapiens (human)
Schaffer collateral - CA1 synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic density membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M1Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
cell surfaceSodium-dependent noradrenaline transporter Homo sapiens (human)
membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
presynaptic membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
axonSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
chromosome, telomeric regionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
nucleusNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
chromosomeNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
nucleolusNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cytoplasmNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
mitochondrionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
centrosomeNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
centrioleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
spindleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cytosolNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
microtubuleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
plasma membraneNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
growth coneNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
midbodyNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
paranodal junctionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
paranode region of axonNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
perikaryonNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
myelin sheathNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
lateral loopNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
Schmidt-Lanterman incisureNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
juxtaparanode region of axonNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
perinuclear region of cytoplasmNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
mitotic spindleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
meiotic spindleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
glial cell projectionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
heterochromatinNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
chromatin silencing complexNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
nucleusNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
nucleolusNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cytoplasmNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
ESC/E(Z) complexNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cytosolNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
fibrillar centerNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nucleusNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nuclear envelopeNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nuclear inner membraneNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nucleoplasmNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nucleolusNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cytoplasmNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
mitochondrionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cytosolNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
PML bodyNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
eNoSc complexNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
chromatinNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
euchromatinNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
heterochromatinNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
chromatin silencing complexNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
rDNA heterochromatinNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nucleusNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nuclear inner membraneNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nucleoplasmNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nucleoplasmNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
mitochondrionNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
mitochondrial matrixNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
protein-containing complexNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
nucleusNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (128)

Assay IDTitleYearJournalArticle
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID347350Antidiabetic activity in diet-induced obesity C57BL/6 mouse model assessed as reduction of fed blood glucose level at 100 mg/kg, po daily once for 1 week relative to control2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
AID331064Reduction of insulin level in chow-fed C57BL/6 mouse2007Nature, Nov-29, Volume: 450, Issue:7170
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
AID331040Activation of human SIRT1 expressed in Escherichia coli BL21 by mass spectrometry assay2007Nature, Nov-29, Volume: 450, Issue:7170
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
AID331045Activation of SIRT1 in human U2OS cells assessed as decrease in p53 deacetylation level at 0.10 uM2007Nature, Nov-29, Volume: 450, Issue:7170
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
AID331063Reduction of hyperinsulinemia in DIO C57BL/6 mouse model at 100 mg/kg, po after 4 weeks2007Nature, Nov-29, Volume: 450, Issue:7170
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
AID347724Antidiabetic activity in genetic Zucker fa/fa rat model assessed as reduction of fed blood glucose level at 100 mg/kg, po daily once after 3 weeks relative to control2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
AID764860Activation of human recombinant SIRT1 at 10 uM preincubated for 60 mins prior to substrate addition measured after 60 mins by fluorescence assay2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Search for a novel SIRT1 activator: structural modification of SRT1720 and biological evaluation.
AID347733Inhibition of CYP3A4 at 25 uM2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
AID331051Activation of human SIRT1-E (225-664) construct by mass spectrometry assay relative to control2007Nature, Nov-29, Volume: 450, Issue:7170
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
AID347735Inhibition of muscarinic M1 receptor2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
AID1466439Inhibition of SIRT3 (unknown origin)2017European journal of medicinal chemistry, Jul-07, Volume: 134Discovery of 2-((4,6-dimethylpyrimidin-2-yl)thio)-N-phenylacetamide derivatives as new potent and selective human sirtuin 2 inhibitors.
AID331059Terminal half life in Sprague-Dawley rat at 100 mg/kg/day, po2007Nature, Nov-29, Volume: 450, Issue:7170
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
AID331076Reduction in hepatic gluconeogenesis in Zucker fa/fa rat assessed as glucose response by pyruvate tolerance test relative to control2007Nature, Nov-29, Volume: 450, Issue:7170
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
AID331082Reduction of blood glucose level in po dosed Zucker fa/fa rat assessed as glucose level after 3 weeks by glucose tolerance test2007Nature, Nov-29, Volume: 450, Issue:7170
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
AID347348AUC in Sprague-Dawley rat at 100 mg/kg, po or 10 mg/kg, iv2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
AID331069Reduction of blood glucose level in po dosed Zucker fa/fa rat assessed as glucose level after 3 weeks2007Nature, Nov-29, Volume: 450, Issue:7170
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
AID500672Activation of human SirT2 protein fluorescence polarization assay2008Nature chemical biology, Oct, Volume: 4, Issue:10
Chemical probes for histone-modifying enzymes.
AID331041Activation of SIRT2 by mass spectrometry assay2007Nature, Nov-29, Volume: 450, Issue:7170
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
AID331057AUC in C57BL/6 mouse at 100 mg/kg/day, po2007Nature, Nov-29, Volume: 450, Issue:7170
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
AID347725Antidiabetic activity in genetic Zucker fa/fa rat model assessed as reduction of glucose production at 100 mg/kg, po daily once after 3 weeks by pyruvate tolerance test2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
AID347741Mutagenic activity in Salmonella Typhimurium TA98 in presence of S9 activation2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
AID347722Toxicity in diet-induced obesity C57BL/6 mouse model assessed as hemoglobin at 100 mg/kg, po daily once for 10 weeks2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
AID331080Effect on body weight in diabetic Lep ob/ob mouse model at 100 mg/kg, po2007Nature, Nov-29, Volume: 450, Issue:7170
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
AID331066Reduction of blood glucose level in diabetic Lep ob/ob mouse model at 100 mg/kg, po after 1 week2007Nature, Nov-29, Volume: 450, Issue:7170
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
AID347344AUC in C57BL/6 mouse at 100 mg/kg, po or 10 mg/kg, iv2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
AID764859Activation of human recombinant SIRT1 at 100 uM preincubated for 60 mins prior to substrate addition measured after 60 mins by fluorescence assay2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Search for a novel SIRT1 activator: structural modification of SRT1720 and biological evaluation.
AID347343Terminal half life in C57BL/6 mouse at 100 mg/kg, po or 10 mg/kg, iv2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
AID331074Increase in insulin sensitivity in po dosed Zucker fa/fa rat assessed as hepatic glucose production relative to control2007Nature, Nov-29, Volume: 450, Issue:7170
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
AID735924Activation of N-terminal His6-tagged SIRT1 (156 to 664 amino acid residues) (unknown origin) expressed in Escherichia coli BL21(DE3) using ac-RHKKac-AMC as substrate at 50 uM after 45 mins by fluorimetric analysis relative to control2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery and mechanism study of SIRT1 activators that promote the deacetylation of fluorophore-labeled substrate.
AID347716Antidiabetic activity in diet-induced obesity C57BL/6 mouse model assessed as reduction of plasma insulin level at 100 mg/kg, po daily once after 10 weeks2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
AID331052Activation of human SIRT1-F (230-664) construct by mass spectrometry assay relative to control2007Nature, Nov-29, Volume: 450, Issue:7170
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
AID347336Activation of human SIRT1 expressed in Escherichia coli BL21Start assessed as maximum activation of enzyme activity by mass spectrometry assay2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
AID347732Inhibition of CYP2D6 at 25 uM2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
AID331073Increase in insulin-induced glucose disposal rate into skeletal muscle in po dosed Zucker fa/fa rat relative to control2007Nature, Nov-29, Volume: 450, Issue:7170
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
AID331077Activation of human SIRT1 assessed as decrease in Km of enzyme for acetylated peptide substrate by mass spectrometry assay2007Nature, Nov-29, Volume: 450, Issue:7170
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
AID347727Antidiabetic activity in genetic Zucker fa/fa rat model assessed as increase in glucose disposal rate at 100 mg/kg, po daily once after 4 weeks by hyperinsulinemic-euglycemic clamp2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
AID347738Inhibition of sodium channel site 22009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
AID347351Antidiabetic activity in diet-induced obesity C57BL/6 mouse model assessed as reduction of fed blood glucose level at 100 mg/kg, po daily once for 1 week after 10 weeks2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
AID331042Activation of SIRT3 by mass spectrometry assay2007Nature, Nov-29, Volume: 450, Issue:7170
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
AID331053Activation of human SIRT1-G (235-664) construct by mass spectrometry assay relative to control2007Nature, Nov-29, Volume: 450, Issue:7170
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
AID1896329Activation of human N-terminal hexa-histidine tagged SIRT1 expressed in Escherichia coli BL21 (DE3) using peptide substrate by fluorescence polarization assay2022Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21
The Pursuit of Enzyme Activation: A Snapshot of the Gold Rush.
AID347341Oral bioavailability in C57BL/6 mouse at 100 mg/kg2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
AID331050Activation of human SIRT1-D (219-664) construct by mass spectrometry assay relative to control2007Nature, Nov-29, Volume: 450, Issue:7170
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
AID723626Inhibition of human Sirt5 deacetylation activity using FKRGVL-acetylLys-EYGVKV as substrate at 100 uM after 60 mins by glutamate dehydrogenase-coupled assay2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Inhibition of the human deacylase Sirtuin 5 by the indole GW5074.
AID347349Antidiabetic activity in ob/ob mouse model assessed as reduction of fasting blood glucose level at 100 mg/kg, po daily once after 1 week relative to control2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
AID331060AUC in Sprague-Dawley rat at 100 mg/kg/day, po2007Nature, Nov-29, Volume: 450, Issue:7170
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
AID347721Toxicity in diet-induced obesity C57BL/6 mouse model assessed as red blood count at 100 mg/kg, po daily once for 10 weeks2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
AID347342Cmax in C57BL/6 mouse at 100 mg/kg, po or 10 mg/kg, iv2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
AID347734Inhibition of adrenergic alpha2A receptor2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
AID331055Bioavailability in C57BL/6 mouse at 100 mg/kg/day, po2007Nature, Nov-29, Volume: 450, Issue:7170
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
AID347726Antidiabetic activity in genetic Zucker fa/fa rat model assessed as increase in glucose infusion rate at 100 mg/kg, po daily once after 4 weeks by hyperinsulinemic-euglycemic clamp2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
AID1236441Antitrypanosomal activity against Trypanosoma brucei brucei 427 assessed as inhibition of parasite proliferation measured as ATP levels after 48 hrs by luciferase-based assay2015Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16
Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT).
AID331065Increase in mitochondrial capacity in DIO C57BL/6 mouse model assessed as citrate synthase activity at 100 mg/kg, po after 10 weeks2007Nature, Nov-29, Volume: 450, Issue:7170
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
AID331078Reduction of glucose levels in DIO C57BL/6 mouse model at 100 mg/kg, po during insulin tolerance test2007Nature, Nov-29, Volume: 450, Issue:7170
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
AID347717Antidiabetic activity in diet-induced obesity C57BL/6 mouse model assessed as reduction of plasma insulin level at 5 mg/kg, po daily once after 10 weeks2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
AID347730Inhibition of CYP2C19 at 25 uM2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
AID347740Mutagenic activity in Salmonella Typhimurium TA100 in absence of S9 activation2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
AID347737Inhibition of norepinephrine transporter2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
AID1628082Activation of full-length GST-tagged recombinant human SIRT1 assessed as enzyme activity obtained with subtraction of intrinsic fluorescence using H3K9 as substrate at 50 uM after 30 mins by SIRTainty assay2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
1,4-Dihydropyridines Active on the SIRT1/AMPK Pathway Ameliorate Skin Repair and Mitochondrial Function and Exhibit Inhibition of Proliferation in Cancer Cells.
AID331047Activation of human SIRT1-A (156-664) construct by mass spectrometry assay relative to control2007Nature, Nov-29, Volume: 450, Issue:7170
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
AID331049Activation of human SIRT1-C construct by mass spectrometry assay relative to control2007Nature, Nov-29, Volume: 450, Issue:7170
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
AID347345Oral bioavailability in Sprague-Dawley rat at 100 mg/kg2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
AID723620Inhibition of human Sirt5 desuccinylation activity using SKEYFS-succinylLys-QK as substrate at 100 uM after 60 mins by glutamate dehydrpgenase-coupled assay2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Inhibition of the human deacylase Sirtuin 5 by the indole GW5074.
AID347729Inhibition of CYP1A at 25 uM2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
AID331072Increase in glucose disposal rate in po dosed Zucker fa/fa rat relative to control2007Nature, Nov-29, Volume: 450, Issue:7170
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
AID331075Increase in adipose insulin sensitivity in po dosed Zucker fa/fa rat assessed as plasma free fatty acid level relative to control2007Nature, Nov-29, Volume: 450, Issue:7170
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
AID347718Antidiabetic activity in C57BL/6 mouse assessed as overt sign of hypoglycemia at 100 mg/kg, po daily once after 10 weeks2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
AID347739Mutagenic activity in Salmonella Typhimurium TA98 in absence of S9 activation2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
AID347723Toxicity in diet-induced obesity C57BL/6 mouse model assessed as hematocrit at 100 mg/kg, po daily once for 10 weeks2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
AID331056Terminal half life in C57BL/6 mouse at 100 mg/kg/day, po2007Nature, Nov-29, Volume: 450, Issue:7170
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
AID347736Inhibition of muscarinic M2 receptor2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
AID735925Activation of N-terminal His6-tagged SIRT1 (156 to 664 amino acid residues) (unknown origin) expressed in Escherichia coli BL21(DE3) using ac-RHKKac-AMC as substrate after 45 mins by fluorometric analysis2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery and mechanism study of SIRT1 activators that promote the deacetylation of fluorophore-labeled substrate.
AID347728Inhibition of human ERG by patch clamp method2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
AID347731Inhibition of CYP2C9 at 25 uM2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
AID331071Increase in glucose infusion rate required to to maintain euglycaemia in po dosed Zucker fa/fa rat relative to control2007Nature, Nov-29, Volume: 450, Issue:7170
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
AID331061Reduction of fasting blood glucose in DIO C57BL/6 mouse model at 100 mg/kg, po assessed as glucose level by glucose tolerance test2007Nature, Nov-29, Volume: 450, Issue:7170
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
AID1896330Activation of human N-terminal hexa-histidine tagged SIRT1 expressed in Escherichia coli BL21 (DE3) using peptide substrate by fluorescence polarization assay relative to control2022Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21
The Pursuit of Enzyme Activation: A Snapshot of the Gold Rush.
AID347719Liver toxicity in diet-induced obesity C57BL/6 mouse model at 100 mg/kg, po daily once after 10 weeks2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
AID331054Activation of human SIRT1-H (240-664) construct by mass spectrometry assay relative to control2007Nature, Nov-29, Volume: 450, Issue:7170
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
AID331070Reduction of blood insulin level in po dosed Zucker fa/fa rat after 3 weeks by glucose tolerance test2007Nature, Nov-29, Volume: 450, Issue:7170
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
AID347346Cmax in Sprague-Dawley rat at 100 mg/kg, po or 10 mg/kg, iv2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
AID331048Activation of human SIRT1-B (172-664) construct by mass spectrometry assay relative to control2007Nature, Nov-29, Volume: 450, Issue:7170
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
AID347742Mutagenic activity in Salmonella Typhimurium TA100 in presence of S9 activation2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
AID1628081Activation of full-length GST-tagged recombinant human SIRT1 assessed as enzyme activity obtained without subtraction of intrinsic fluorescence using H3K9 as substrate at 50 uM after 30 mins by SIRTainty assay2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
1,4-Dihydropyridines Active on the SIRT1/AMPK Pathway Ameliorate Skin Repair and Mitochondrial Function and Exhibit Inhibition of Proliferation in Cancer Cells.
AID347352Antidiabetic activity in diet-induced obesity C57BL/6 mouse model assessed as reduction of plasma insulin level at 100 mg/kg, po daily once after 2 weeks2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
AID347720Toxicity in diet-induced obesity C57BL/6 mouse model assessed as white blood count at 100 mg/kg, po daily once for 10 weeks2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
AID347335Activation of human SIRT1 expressed in Escherichia coli BL21Start assessed as concentration required to increase 50% enzyme activity by mass spectrometry assay2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
AID347347Terminal half life in Sprague-Dawley rat at 100 mg/kg, po or 10 mg/kg, iv2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
AID331058Bioavailability in Sprague-Dawley rat administered at 10 mg/kg, iv2007Nature, Nov-29, Volume: 450, Issue:7170
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508591NCATS Rat Liver Microsome Stability Profiling2020Scientific reports, 11-26, Volume: 10, Issue:1
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508612NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Highly predictive and interpretable models for PAMPA permeability.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID686947qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1645871NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling in pH 5 buffer2022Bioorganic & medicinal chemistry, 02-15, Volume: 56Using in vitro ADME data for lead compound selection: An emphasis on PAMPA pH 5 permeability and oral bioavailability.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1346060Human sirtuin 1 (3.5.1.- Histone deacetylases (HDACs))2007Nature, Nov-29, Volume: 450, Issue:7170
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (154)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's8 (5.19)29.6817
2010's109 (70.78)24.3611
2020's37 (24.03)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.20 (24.57)
Research Supply Index5.06 (2.92)
Research Growth Index5.59 (4.65)
Search Engine Demand Index39.34 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews10 (6.37%)6.00%
Case Studies0 (0.00%)4.05%
Observational1 (0.64%)0.25%
Other146 (92.99%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]